Compliance with prophylaxis for respiratory syncytial virus infection in a home setting

Pediatric Infectious Disease Journal

Volumn 23, Issue 4, 2004, Pages 318-322

  Golombek, Sergio G ^a   Berning, Frank ^b   Lagamma, Edmund F ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b Optimal Care of New York   (United States)

Author keywords

Home administration; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ANTIBODY TITER; ARTICLE; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HOME CARE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFANT; LIFESTYLE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NEWBORN INTENSIVE CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOME CARE SERVICES; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAMUSCULAR; MALE; OFFICE VISITS; PATIENT COMPLIANCE; PROBABILITY; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC;

EID: 1942420321     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200404000-00008     Document Type: Article

References (27)

1. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000;283:499-505.
2. AAP Committee on Infectious Disease and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IVIG. Pediatrics 1998;102:1211-18.
3. Johnson S, Oliver C, Prince G, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus (RSV). J Infect Dis 1997;176:1215-24.
4. Malley R, DeVincenzo JF, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in travheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998;178:1555-61.
5. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis associated hospitalizations among US children, 1980-1996. JAMA 1999;282:1440-6.
6. Connor EM and the Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
7. Singleton RJ, Petersen KM, Berner JE. Hospitalizations for respiratory syncytial virus infection in Alaska Native children. Pediatr Infect Dis J 1995;14:26-30.
8. Lowther SA, Shay DK, Holman RC, Clarke MJ, Kaufman SF, Anderson LJ. Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children. Pediatr Infect Dis J 2000;19:11-17.
9. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000;137:865-70.
10. Bulkow LR, Singleton RJ, Karron RA, Harrison LH and the Alaska RSV Study Group. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 2002;109:210-16.
11. Respiratory syncytial virus activity: United States, 1999-2000 season. MMWR 2000;49:1091-3.
12. Centers for Disease Control and Prevention. Respiratory syncytial virus activity: United States, 1999-2000 season. JAMA 2001;285:287-8.
13. Respiratory syncytial virus activity: United States, 2000-01 season. MMWR 2002;51:26-8.
14. Bockova J, O'Brien KL, Oski J, et al. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. Pediatrics 2002 Aug; 110(2 Pt 1):e20.
15. Yun B, Kim M, Park J, Choi E, Lee H, Yun C. Viral etiology and epidemiology of acute lower respiratory tract infections in Korean children. Pediatr Infect Dis J 1995;14:1054-9.
16. Dagan R, Landau D, Haikin H, Tal A. Hospitalization of Jewish and Bedouin infants in southern Israel for bronchiolitis caused by respiratory syncytial virus. Pediatr Infect Dis J 1993;12:381-6.
17. Kaneko M, Watanabe J, Kuwahara M, et al. Impact of RSV infection as a cause of lower tract infection in children younger than 3 years of age in Japan. J Infect 2002;44:240-3.
18. Muller-Pebody B, Edmunds WJ, Zambon MC, Gay NJ, Crowcroft NS. Contribution of RSV bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998. Epidemiol Infect 2002;129:99-106.
19. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 2002;96(Suppl B):S1-7.
20. Simoes EAF. Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res 2002;3(Suppl 1):S26-33.
21. Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999;104:894-9.
22. Singleton R, Karron RA, Kruse DG, et al. RSV-associated hospitalizations in Alaska Native infants. Int J Circumpolar Health 1998;57(Suppl 1):255-9.
23. Vogel AM, Lennon DR, Broadbent R, et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J Paediatr Child Health 2002;38:550-4.
24. Weber M, Reno S, Hornbake R, Shillington A. An in-home Synagis program for RSV prevention in high-risk infants. J Managed Care Pharm 2001;7:476-81.
25. Paul DA, Leef KH, Chidekel A, Tran K, Eppes S, Stefano JL. Home delivery of palivizumab: outcomes and compliance in regional preterm infants. Del Med J 2002;74:11-15.
26. Eastern Society for Pediatric Research, Greenwich, CT, March 2002.
27. Golombek SG, Berning F, LaGamma EF. Better compliance and fewer hospitalizations with RSV prophylaxis in a home setting [Abstract 183]. J Invest Med 2002;50:184A.